nach oben

Journal of Cancer Survivorship

Erschienen in:

01.12.2007

Endocrine sequelae of cancer and cancer treatments

verfasst von: Charles J. Stava, Camilo Jimenez, Rena Vassilopoulou-Sellin

Erschienen in: Journal of Cancer Survivorship | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Exposure to cancer and its treatments, including chemotherapy and radiotherapy, may result in late adverse effects including endocrine dysfunction. Endocrine disorders are the most commonly reported long-term complications of cancer treatment, especially by adult survivors of childhood cancers. This review will explore the endocrinologic adverse effects from non-endocrine cancer therapies.

Methods

Searches including various Internet-based medical search engines such as PubMed, Medline Plus, and Google Scholar were conducted for published articles.

Results

One hundred sixty-nine journal articles met the inclusion criteria. They included case reports, systematic analyses, and cohort reports. Endocrine disorders including hypothalamus dysfunction, hypopituitarism, syndrome of inappropriate anti-diuretic hormone secretion, diabetes insipidus, growth hormone disorders, hyperprolactinemia, gonadotropin deficiency, serum thyroid hormone-binding protein abnormalities, hypothyroidism, hyperthyroidism, hypomagnesium, hypocalcemia, hyperparathyroidism, hyperparathyroidism, adrenal dysfunction, gonadal dysfunction, hypertriglyceridemia, hypercholesterolemia, diabetes mellitus, and glycosuria were identified and their association with cancer therapies were outlined.

Discussion/conclusions

The journal articles have highlighted the association of cancer therapies, including chemotherapy and radiotherapy, with endocrine dysfunction. Some of the dysfunctions were more often experienced than others. Especially in patients treated with radiotherapy, some endocrinologic disorders were progressive in nature.

Implications for cancer survivors

Recognition and awareness of endocrine sequelae of cancer treatments may permit for early detection and appropriate follow-up care for cancer survivors, thus improving their overall health and quality of life.

Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor lost in transition.. 1st ed. Washington, DC: National Academies; 2006.

Stava C, Beck M, Schultz PN, Vassilopoulou-Sellin R. Hearing loss among cancer survivors. Oncol Rep 2005;13:1193–9.PubMed

Stava C, Beck M, Vassilopoulou-Sellin R. Cataracts among cancer survivors. Am J Clin Oncol 2005;28:603–8.PubMedCrossRef

Schultz PN, Stava C, Beck ML, Vassilopoulou-Sellin R. Ethnic/racial influences on the physiologic health of cancer survivors. Cancer 2004;100:156–64.PubMedCrossRef

Stava CJ, Lopez A, Vassilopoulou-Sellin R. Health profiles of younger and older breast cancer survivors. Cancer 2006;107:1752–9.PubMedCrossRef

Stava C, Weiss LT, Vassilopoulou-Sellin R. Health profiles of 814 very long-term breast cancer survivors. Clin Breast Cancer 2006;7:228–36.PubMed

Schultz PN, Klein MJ, Beck ML, Stava C, Sellin RV. Breast cancer: relationship between menopausal symptoms, physiologic health effects of cancer treatment and physical constraints on quality of life in long-term survivors. J Clin Nurs 2005;14:204–11.PubMedCrossRef

Stava C, Beck M, Lopez A, Vassilopoulou-Sellin R. Health Profiles of 996 Melanoma Survivors: the MD Anderson Experience. BMC Cancer 2006;6:95.PubMedCrossRef

Stava C, Beck ML, Feng L, Lopez A, Busaidy N, Vassilopoulou-Sellin R. Diabetes mellitus among cancer survivors. J Can Surviv 2007;1:102–115.

10.

Schultz PN, Stava C, Vassilopoulou-Sellin R. Health profiles and quality of life of 518 survivors of thyroid cancer. Head Neck 2003;25:349–56.PubMedCrossRef

11.

Cohen LE. Endocrine late effects of cancer treatment. Endocrinol Metab Clin North Am 2005;34:769–89.PubMedCrossRef

12.

Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 1998;19:144–172.PubMedCrossRef

13.

Brougham MFH, Kelnar CJH, Wallace WHB. The late endocrine effects of childhood cancer treatment. Pediatr Rehab 2002;5:191–201.

14.

Sklar CA. Overview of the effects of cancer therapies; the nature, scale and breadth of the problem. Acta Paediatr Suppl 1999;88:1–4.PubMed

15.

Van Santen HM, de Kraker K, Vulsma T. Endocrine late effects from mult-modality treatment of neuroblastoma. Eur J Cancer 2005;41:1767–74.PubMedCrossRef

16.

Rose SR, Schreiber RE, Kearney NS, Lustig RH, Danish RK, Burghen GA, et al. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab 2004;17:55–66.PubMed

17.

Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM. The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 1998;83:4233–38.PubMedCrossRef

18.

Toogood AA. Endocrine consequences of brain irradiation. Growth Horm IGF Res 2004;14(Suppl A):S118–24.PubMedCrossRef

19.

Agha A, Sherlock M, Brennan S, O, Connor SA, O, Sullivan E, Rogers B, et al. Hypothalamic-pituitary dysfunction after irradiation of non-pituitary brain tumors in adults. J Clin Endocrinol Metab 2005;90:6355–60.PubMedCrossRef

20.

Concha LB, Carlson HE, Heimann A, Lake-Bakaar GV, Paal AF. Interferon-induced hypopituitarism. Am J Med 2003;114:161–3.PubMedCrossRef

21.

Chan WB, Cockram CS. Panhypopituitarism in association with interferon-alpha treatment. Singap Med J 2004;45:93–4.

22.

Langsenlehner T, Stiegler C, Quehenberger F, Feigl GC, Jakse G, Mokry M, et al. Long-term follow up of patients with pituitary macroadenomas after postoperative radiation therapy: analysis of tumor control and functional outcome. Strahlenther Onkol 2007;183:241–7.PubMedCrossRef

23.

Minniti G, Jaffrain-Rea M, Osti M, Esposito V, Santoro A, Solda F, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol 2005;62:210–6.CrossRef

24.

Oberfield SE, Nirenberg A, Allen JC, Cohen H, Donahue B, Prasad V, et al. Hypothalamic–pituitary–adrenal function following cranial irradiation. Horm Res 1997;47:9–16.PubMed

25.

Spoudeas HA, Charmandari E, Brook CG. Hypothalamo-pituitary-adrenal axis integrity after cranial irradiation for childhood posterior fossa tumours. Med Pediatr Oncol 2003;40:224–9.PubMedCrossRef

26.

Sorensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 1995;238:97–110.PubMed

27.

Ishii K, Aoki Y, Sasaki M, Tanaka K. Syndrome of inappropriate secretion of antidiuretic hormone induced by intraarterial cistplatin therapy. Gynecol Oncol 2002;87:150–1.PubMedCrossRef

28.

Kusuki M, Iguchi H, Nakamura A, Nishiura H, Kanazawa A, Yamane H. The syndrome of inappropriate antidiuretic hormone secretion associated with chemotherapy for hypophayryngeal cancer. Acta Otolaryngol Suppl 2004;554:74–7.PubMedCrossRef

29.

Yamomoto Y, Kokubo A, Yonekawa M, Nakanishi K. Syndrome of inappropriate secretion of antidiuretic hormone suddenly occurring in a case following chemotherapy. Gan To Kagaku Ryoho 2005;32:107–9.

30.

Otsuka F, Hayashi Y, Ogura T, Hayakawa N, Ikeda S, Makino H, et al. Syndrome of inappropriate secretion of antidiuretic hormone following intrathoracic cisplatin. Intern Med 1996;35:290–4.PubMed

31.

Robinson C, Jeffries RC, Walsh GC. Inappropriate ADH secretion caused by oat cell carcinoma and relieved by lung resection. Thorax 1980;35:635–7.PubMed

32.

Negro A, Regolisti G, Perazzoli F, Davili S, Sani C, Rossi E. Ifosfamide-induced renal Franconi syndrome with associated nephrogenic diabetes insipidus in an adult patient. Nephrol Dial Transplant 1998;13:1547–9.PubMedCrossRef

33.

Rossi R, Gödde A, Kleinebrand A, Rath B, Jürgens H. Concentrating capacity in ifosfamide-induced severe renal dysfunction. Ren Fail 1995;17:551–7.PubMedCrossRef

34.

Sinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG, et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet 1996;348:578–80.CrossRef

35.

Murray-Lyon IM, Cassar J, Coulson R, Williams R, Ganguli PC, Edwards JC, et al. Further studies on streptozotocin therapy for a multiple-hormone producing islet cell carcinoma. Gut 1971;12:717–20.PubMedCrossRef

36.

Delaney V, de Pertuz Y, Nixon D, Bourke E. Indomethacin in streptozocin-induced nephrogenic diabetes insipidus. Am J Kidney Dis 1987;9:79–83.PubMed

37.

Gleeson HK, Shalet SM. The impact of cancer therapy on the endocrine system in survivors of childhood brain tumors. Endocr Relat Cancer 2004;11:589–602.PubMedCrossRef

38.

Borson-Chazot F, Brue T. Pituitary deficiency after brain radiation therapy. Ann Endocrinol (Paris) 2006;67:303–9.

39.

Bhansali A, Banerjee AK, Chanda A, Singh P, Sharma SC, Mathuriya SN, et al. Radiation-induced brain disorders in patients with pituitary tumors. Australas Radiol 2004;48:339–46.PubMedCrossRef

40.

Jyotsna VP, Singh SK, Chaturvedi R, Neogi B, Bhadada SK, Sahay RK, et al. Cranial irradiation- an unusual case for diabetes insipidus. J Assoc Physicians India 2000;48:1107–8.PubMed

41.

Murray RD, Brennan BM, Rahim A, Shalet SM. Survivors of childhood cancer: long-term endocrine and metabolic problems dwarf the growth disturbance. Acta Paediatr Suppl 1999;88:5–12.PubMed

42.

Román J, Villaizán CJ, García-Foncillas J, Azcona C, Salvador J, Sierrasesúmaga L. Chemotherapy-induced growth hormone deficiency in children with cancer. Med Pediatr Oncol 1995;25:90–5.PubMedCrossRef

43.

Olshan JS, Gubernick J, Packer RJ, D, Angio GJ, Goldwein JW, Willi SM, et al. The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer 1992;70:2013–7.PubMedCrossRef

44.

Marky I, Mellander L, Lannering B, Albertsson-Wikland L. A longitudinal study of growth and growth hormone secretion in children during treatment for acute lymphoblastic leukemia. Med Pediatr Oncol 1991;19:258–64.PubMedCrossRef

45.

Brennan BM, Rahim A, Mackie EM, Eden OB, Shalet SM. Growth hormone status in adults treated for acute lymphoblastic leukemia in childhood. Clin Endocrinol (Oxf) 1998;48:777–83.CrossRef

46.

Hameed R, Zacharin MR. Long-term endocrine effects of cancer treatment: experience of the Royal Children’s Hospital Melbourne. J Paediatr Child Health 2005;41:36–42.PubMedCrossRef

47.

Livesey EA, Hindmarsh PC, Brook CG, Whitton AC, Bloom HJ, Tobias JS, et al. Endocrine disorders following treatment for childhood brain tumours. Br J Cancer 1990;61:622–5.PubMed

48.

Karasek M, Pawlikowski M, Lewinski A. Hyperprolactinemia: causes, diagnosis, and treatment. Endokrynol Pol 2006;57:656–62. (article in Polish).PubMed

49.

Darzy KH, Shalet SM. Hypopituitarism as a consequence of brain tumors and radiotherapy. Pituitary 2005;8:203–11.PubMedCrossRef

50.

Constine LS, Rubin P, Woolf PD, Doane K, Lush CM. Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies. J Clin Oncol 1987;5:1841–51.PubMed

51.

Constine LS, Woolf PD, Cann D, Mick G, McCormick K, Raubertas RF, et al. Hypothalamic–pituitary dysfunction after radiation for brain tumors. N Eng J Med 1993;328:87–94.CrossRef

52.

Ogilvy-Stuart AL, Shalet SM. Effect of radiation on the human reproductive system. Environ Health Perspect 1993;101(Suppl 2):109–16.PubMedCrossRef

53.

Yeung SJ, Gagel RF. Section 40. Complications of cancer and its treatment, 155. Endocrine complications. In: Holland JF, Frei E III, Bast RC Jr, Kufe DW, Pollock RE, Weischselbaum RR, editors. Cancer medicine. 5th ed. Hamilton, Ontario, Canada: BC Decker Inc.; 2000.

54.

Rappaport R, Brauner R, Czernichow P, Thibaud E, Renier D, Zucker JM, et al. Effects of hypothalamic and pituitary irradiation on pubertal development in children with cranial tumors. J Clin Endocrinol Metab 1982;54:1164–8.PubMed

55.

Bartalena L, Martino E, Antonelli A, Pacchiarotti A, Robbins J, Pinchera A. Effect of the antileukemic agent l-asparaginase on thyroxine-binding globulin and albumin synthesis in cultured human hepatoma (HEP G2) cells. Endocrinology 1986;119:1185–8.PubMed

56.

Surks MI, Sievert R. Drugs and thyroid function. N Engl J Med 1995;333:1688–94.PubMedCrossRef

57.

Dong BJ. How medications affect thyroid function. West J Med 2000;172:102–6.PubMedCrossRef

58.

Mamby CC, Love RR, Lee KE. Thyroid function test changes with adjuvant tamoxifen therapy in postmenopausal women with breast cancer. J Clin Oncol 1995;13:854–7.PubMed

59.

Djurica SN, Plećas B, Milojević Z, Petrović M, Cirović M, Tasovac-Ponomarev D. Direct effects of cytostatic therapy on the functional state of the thyroid gland and TBG in serum of patients. Exp Clin Endocrinol 1990;96:57–63.PubMedCrossRef

60.

Paulino AC. Hypothyroidism in children with medulloblastoma: a comparison of 3600 and 2340 cGy craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 2002;53:543–7.PubMedCrossRef

61.

Chianese-Bullock KA, Woodson EM, Tao H, Boerner SA, Smolkin M, Grosh WW, et al. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother 2005;28:412–9.PubMedCrossRef

62.

Bohbot NL, Young J, Orgiazzi J, Buffet C, François M, Bernard-Chabert B, et al. Interferon-alpha-induced hyperthyroidism: a three-stage evolution from silent thyroiditis towards Graves’ disease. Eur J Endocrinol 2006;154:367–72.PubMedCrossRef

63.

Kruit WH, Bolhuis RL, Goey SH, Jansen RL, Eggermont AM, Batchelor D, et al. Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol 1993;11:921–4.PubMed

64.

Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casari P, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007;92:3531–4.PubMedCrossRef

65.

Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:81–3.PubMed

66.

Wong F, Rosen LS, Mulay M, Vanvught A, Dinolfo A, Tomoda C, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007;17:351–5.PubMedCrossRef

67.

Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660–4.PubMed

68.

Maitland ML, Ratain MJ. Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med 2006;145:702–3.PubMed

69.

Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006;42:3127–39.PubMedCrossRef

70.

Garfield DH, Hercbergs A, Davis PJ. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007;99:975–6.PubMedCrossRef

71.

Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999;340:1075–9.PubMedCrossRef

72.

Bessho R, Ohta K, Akanuma A, Sakata K. Dosimetry of radiation scattered to thyroid gland from prophylactic cranial irradiation for childhood leukemia. Pediatr Hematol Oncol 1994;11:47–53.PubMed

73.

Madanat LM, Lahteenmaki PM, Alin J, Salmi TT. The natural history of thyroid function abnormalities after treatment for childhood cancer. Eur J Cancer 2007;43:1161–70.PubMedCrossRef

74.

Jereczek-Fossa BA, Alterio D, Jassem J, Gibelli B, Tradati N, Orecchia R. Radiotherapy-induced thyroid disorders. Cancer Treat Rev 2004;30:369–84.PubMedCrossRef

75.

Chin D, Sklar C, Donahue B, Uli N, Geneiser N, Allen J, et al. Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma/primitive neuroectodermal tumors: a comparison of hyperfractionated versus conventional radiotherapy. Cancer 1997;80:798–804.PubMedCrossRef

76.

Littley MD, Shalet SM, Morgenstern GR, Deakin DP. Endocrine and reproductive dysfunction following fractionated total body irradiation in adults. Quart J Med 1991;78:265–74.PubMed

77.

Ishiguro H, Yasuda Y, Tomita Y, Shinagawa T, Shimizu T, Morimoto T, et al. Long-term follow-up of thyroid function in patients who received bone marrow transplantation during childhood and adolescence. J Clin Endocrinol Metab 2004;89:5981–6.PubMedCrossRef

78.

Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med 1991;325:599–605.PubMedCrossRef

79.

Loeffler JS, Tarbell NJ, Garber JR, Mauch P. The development of Graves’ disease following radiation therapy in Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1988;14:175–8.PubMed

80.

Jacobson DR, Fleming BJ. Grave’s disease with ophthalmopathy following radiotherapy for Hodgkin’s disease. Am J Med Sci 1984;288:217–20.PubMedCrossRef

81.

Al-Anazi KA, Inam S, Jeha MT, Judzewitch R. Thyrotoxic crisis induced by cytotoxic chemotherapy. Support Care Cancer 2005;13:196–8.PubMedCrossRef

82.

Kabbaj N, Guedira MM, El Atmani H, El Alaoui M, Mohammadi M, Benabed K, et al. Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study. Ann Endocrinol (Paris) 2006;67:343–7.

83.

Umemoto S, Izumi K, Kanno H. Two cases of hyperthyroidism induced by interferon-alpha therapy for renal cell carcinoma. Hinyokika Kiyo 2007;53:225–9. (article in Japanese).PubMed

84.

Sklar C, Whitton J, Mertens A, Stovall M, Green D, Marina N, et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the childhood cancer survivor study. J Clin Endocrinol Metab 2000;85:3227–32.PubMedCrossRef

85.

Nishiyama K, Kozuka T, Higashihara T, Miyauchi K, Okagawa K. Acute radiation thyroiditis. Int J Radiat Oncol Biol Phys 1996;6:1221–4.CrossRef

86.

Atsmon J, Dolev E. Drug-induced hypomagnesaemia: scope and management. Drug Safety 2005;28:763–88.PubMedCrossRef

87.

Elisaf M, Milionis H, Siamipoulos KC. Hypomagnesemic hypokalemia and hypocalcemia: clinical and laboratory characteristics. Miner Electrolyte Metab 1997;23:105–12.PubMed

88.

Buckley JE, Clark VL, Meyer TJ, Pearlman NW. Hypomagnesemia after cisplatin combination chemotherapy. Arch Intern Med 1984;114:2347–8.CrossRef

89.

Stöhr W, Paulides M, Bielack S, Jürgens H, Koscielniak E, Rossi R, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer 2007;48:140–7.PubMedCrossRef

90.

Lyman NW, Hemalatha C, Viscuso RL, Jacobs MG. Cisplatin-induced hypocalcemia and hypomagnesemia. Arch Intern Med 1980;140:1512–4.CrossRef

91.

Baeksgaard K, Sorensen JB. Acute tumor lysis syndrome in solid tumors—a case report and review of the literature. Cancer Chemother Pharmacol 2003;51:187–92.PubMed

92.

Furue H. Interferons—its method of administration and adverse effect related to pharmacokinetics. Gan to Kagaku Ryoho 1984;11:186–93. (article in Japanese).PubMed

93.

Tanvetyanon T, Choudhury AM. Hypocalcemia and azootemia associated with zoledronic acid and interferon alfa. Ann Pharmacother 2004;38:418–21. (Epub 2004 Jan 23).PubMedCrossRef

94.

Rosen IB, Strawbridge HG, Bain J. A case of hyperparathyroidism associated with radiation to the head and neck area. Cancer 1975;36:1111–4.PubMedCrossRef

95.

Stephen AE, Chen KT, Milas M, Siperstein AE. The coming of age of radiation-induced hyperparathyroidism: evolving patterns of thyroid and parathyroid disease after head and neck irradiation. Surgery 2004;136:1143–53.PubMedCrossRef

96.

Hedman I, Hansson G, Lundberg LM, Tisel LE. A clinical evaluation of radiation-induced hyperparathyroidism based on 148 surgically treated patients. World J Surg 1984;8:96–105.PubMedCrossRef

97.

Fiorica V, Males JL. Hyperparathyroidism after radiation of the neck: a case report and review of the literature. Am J Med Sci 1979;278:223–8.PubMed

98.

Thorp MA, Levitt NS, Mortimore S, Isaacs S. Parathyroid and thyroid function five years after treatment of laryngeal and hypopharyngeal carcinoma. Clin Otolaryngol Allied Sci 1999;24:104–8.PubMedCrossRef

99.

Harvey PW, Everett DJ, Springall CJ. Adrenal toxicity: a strategy for assessment of functional toxicity to the adrenal cortex and steroidogenesis. J Appl Toxicol 2007;27:103–15.PubMedCrossRef

100.

Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002;16:225–43.PubMedCrossRef

101.

Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 2005;6:386–94.PubMed

102.

van Ditzhuijsen CI, van der Weijer R, Haak HR. Adrenocorticol carcinoma. Neth J Med 2007;65:55–60.PubMed

103.

Allolio B, Fassnacht M. Clinical review: Adrenocorticol carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027–37.PubMedCrossRef

104.

Schteingart DE. Adjuvant mitotane therapy of adrenal cancer—use and controversy. N Engl J Med 2007;356:2415–8.PubMedCrossRef

105.

Smalley RV, Wall RL. Two cases of busulfan toxicity. Ann Intern Med 1966;64:154–64.PubMed

106.

Ward HN, Konikov N, Reinhard EH. Cytologic dysplasia occurring after busulfan (Myleran) therapy. A syndrome resembling adrenocorticol insufficiency and atrophic bronchitis. Ann Intern Med 1965;63:654–60.PubMed

107.

Kyle RA, Schwartz RS, Oliner HL, Dameshek W. A syndrome resembling adrenal corticol insufficiency associated with long term busulfan (Myleran) therapy. Blood 1961;18:497–510.

108.

Harrold BP. Syndrome resembling Addison’s disease following prolonged treatment with busulphan. Br Med J 1966;1:463–4.PubMed

109.

GlaxoSmithKline. Myleran, Prescribing Information. Jan 2004. GlaxoSmithKline.

110.

Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367–73.PubMedCrossRef

111.

Kobayashi K, Weiss RE, Vogelzang NJ, Vokes EE, Janisch L, Ratain MJ. Mineralocorticoid insufficiency due to suramin therapy. Cancer 1996;78:2411–20.PubMedCrossRef

112.

Dorfinger K, Niederle B, Vierhapper H, Astrid W, Czernin S, Nowotny P, et al. Suramin and the human adrenocortex: results of experimental and clinical studies. Surgery 1991;110:1100–5.PubMed

113.

Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995;122:843–5.PubMed

114.

Wingard JR, Vogelsang GB, Deeg HJ. Stem sell transplantation: supportive care and long-term complications. Hematology 2002;1:422–44.CrossRef

115.

Schmiegelow M. Endocrinological late effects following radiotherapy and chemotherapy of childhood brain tumours. Dan Med Bull 2006;53:326–41.PubMed

116.

Stricker CT. Endocrine effects of breast cancer treatment. Sem Oncol Nurs 2007;23:55–70.CrossRef

117.

Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006;24:5769–79.PubMedCrossRef

118.

Wallace WH, Shalet SM, Crowne EC, Morris-Jones PH, Gattamaneni HR, Price DA. Gonadal dysfunction due to cis-platinum. Med Pediatr Oncol 1989;17:409–13.PubMedCrossRef

119.

Brydoy M, Fossa SD, Dahl O, Bjoro T. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol 2007;46:480–9.PubMedCrossRef

120.

Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP vs. ABVD. Eur J Cancer Clin Oncol 1985;21:601–5.PubMedCrossRef

121.

Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 1998;27:927–43.PubMedCrossRef

122.

Howell SJ, Radford JA, Ryder WD, Shalet SM. Testicular function after cytotoxic chemotherapy; evidence of Leydig cell insufficiency. J Clin Oncol 1999;17:493–8.

123.

Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W. The impact of chemotherapy on Leydig cell function in long-term survivors of germ cell tumors. Cancer 2001;91:1297–1303.PubMedCrossRef

124.

Gleeson HK, Shalet SM. Endocrine complications of neoplastic diseases in children and adolescents. Curr Opin Pediatr 2001;13:346–51.PubMedCrossRef

125.

Howell SJ, Shalet SM. Spermatogenesis after cancer treatment: damage and recovery. J Natl Cancer Inst Monogr 2005;34:12–7.PubMedCrossRef

126.

Heikens J, Behrendt H, Adriaanse R, Berghout A. Irreversible gonadal damage in male survivors of pediatric Hodgkin’s disease. Cancer 1996;78:2020–4.PubMedCrossRef

127.

Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14:2923–32.PubMed

128.

Bramswig GL, Shlegel W, Jurgens H, Schellong G. The effects of etoposide on testicular function in boys treated for Hodgkin’s disease. Cancer 1998;83:2217–22.PubMedCrossRef

129.

Wiechno P, Demkow T, Kubiak K, Sadowska M, Kaminska J. The quality of life and hormonal disturbances in testicular cancer survivors in cisplatin era. Eur Urol 2007;52:1448–54.PubMedCrossRef

130.

Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ. Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 1996;73:1108–14.PubMed

131.

Arlt W, Hove U, Muller B, Reincke M, Berweiler U, Schwab F, et al. Frequent and frequently overlooked: treatment-induced endocrine dysfunction in adult long-term survivors of primary brain tumors. Neurology 1997;47:498–506.

132.

Bryce CJ, Shenkier T, Gelmon K. Menstrual disruption in premenopausal breast cancer patients receiving CMF (IV) vs. AC adjuvant chemotherapy. Breast Cancer Res Treat 1998;50:284.

133.

Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002;9:466–72.PubMed

134.

Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718–29.PubMed

135.

Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006;24:1045–51.PubMedCrossRef

136.

Minton SE, Munster PN. Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer. Cancer Control 2002;9:466–72.PubMed

137.

Knobf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. The Oncologist 2006;11:96–110.PubMedCrossRef

138.

Tham YL, Sexton K, Weiss H, Elledge R, Friedman LC, Kramer R. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007;30:126–32.PubMedCrossRef

139.

Monga U. Sexual functioning in cancer patients. Sex Disabil 2002;20:277–95.CrossRef

140.

Tauchmanova L, Selleri C, DeRosa G, Pagano L, Orio F, Lombardi G, et al. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer 2002;95:1076–84.PubMedCrossRef

141.

Thibaud E, Rodriguez-Macias K, Trivin C, Esperou H, Michon J, Brauner R. Ovarian function after bone marrow transplantation during childhood. Bone Marrow Transplant 1998;21:287–90.PubMedCrossRef

142.

Meistrich ML, Vassilopoulou-Sellin R, Lipschultz LI. Adverse effects of treatment: gonadal dysfunction. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 5th ed. New York: Lippincott-Raven; 1997. p. 2758–73.

143.

Standeven AM, Beard RL, Johnson AT, Boehm MF, Escobar M, Heyman RA, et al. Retinoid-induced hypertriglyceridemia in rats is mediated by retinoic Acid receptors. Fundam Appl Toxicol 1996;33:264–72.PubMedCrossRef

144.

Dillman RO, Shea WM, Tai DF, Mahdavi K, Barth NM, Kharkar BR, et al. Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. Neuro-Oncol 2001;3:35–41.PubMed

145.

Rodondi N, Darioli R, Ramelet AA, Hohl D, Lenain V, Perdrix J, et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic therapy for acne: a pharmacogenetic study. Ann Intern Med 2002;136:582–9.PubMed

146.

Stoll D, Binnert C, Mooser V, Tappy L. Short-term administration of isotretinoin elevates plasma triglyceride concentrations without affecting insulin sensitivity in health humans. Metabolism 2004;53:4–10.PubMedCrossRef

147.

Hoffman-La Roche Inc. Roferon-A, Complete product information. Sept 2003.

148.

Peñarrubia MJ, Steegmann JL, Lavilla E, Casado F, Requena MJ, Picõ M, et al. Hypertriglyceridemia may be severe in CML patients treated with interferon-alpha. Am J Hematol 1995;49:240–1.PubMedCrossRef

149.

Wong SF, Jakowatz JG, Taheri R. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma. Ann Pharmacother 2004;38:1655–9.PubMedCrossRef

150.

Raghavan D, Cox K, Childs A, Grygiel J, Sullivan D. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 1992;10:1375–9.

151.

Gietema JA, Sleijfer DT, Willemse PH, Scraffordt Koops H, van Ittersum E, Verschuren WM, et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992;116:709–15.PubMed

152.

Fenton DW, Verma S, Venner P, Sawhney R, Mackey JR. The lack of long-term effect of cisplatin based combination chemotherapy on serum cholesterol for treatment of testicular cancer. J Urol 2002;168:1971–4.PubMedCrossRef

153.

Vassilopoulou-Sellin R, Samaan NA. Mitotane administration: an unusual cause of hypercholesterolemia. Horm Metab Res 1991;23:619–20.PubMedCrossRef

154.

Toma S, Bonelli L, Sartoris A, Mira E, Antonelli A, Beatrice F, et al. 13-cis Retinoic acid in head and neck cancer chemoprevention: results of a randomized trial from the Italian Head and Neck Chemoprevention Study Group. Oncol Rep 2004;11:1297–305.PubMed

155.

Parsons SK, Skapek SX, Neufeld EJ, Kuhlman C, Young ML, Donnelly M, et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood 1997;89:1886–95.PubMed

156.

Maher VM, Trainer PJ, Scoppola A, Anderson JV, Thompson GR, Besser GM. Possible mechanism and treatment of o,p′DDD-induced hypercholesterolaemia. Q J Med 1992;84:671–9.PubMed

157.

Lasa O, Izu R, Acebo E, Eguino P, Díaz-Pérez JL. Treatment of cutaneous T-cell lymphomas with bexarotene. Actas Dermo-sifiliogr 2006;97:102 (article in Spanish).

158.

Lowe MN, Plosker GL. Bexarotene. Am J Clin Dermatol 2000;1:245–50. (discussion 251–2).PubMedCrossRef

159.

Zalewska-Szewczyk B, Przybysz K, Kowalewska-Pietrzak M, Stolarska M, Bodalski J. Iatrogenic hyperlipidemia after l-asparaginase and glucocorticoid treatment in two children with acute lymphoblastic leukemia. Pol Merkur Lekarski 2003;15:256–8. (article in Polish).PubMed

160.

Athanassiadou F, Kourti M, Papageorgiou T, Stamou M, Makedou A, Boufidou A. Severe hyperlipidemia in a child with acute lymphoblastic leukemia treated with l-asparaginase and prednisone. Pediatr Int 2004;46:743–4.PubMedCrossRef

161.

Steinherz PG. Transient, severe hyperlipidemia in patients with acute lymphoblastic leukemia treated with prednisone and asparaginase. Cancer 1994;74:3234–9.PubMedCrossRef

162.

Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Kojima M. Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy 2004;24:508–14.PubMedCrossRef

163.

Markell MS, Friedman EA. Hyperlipidemia after organ transplantation. Am J Med 1989;87:61N–7N.PubMed

164.

Deters M, Kirchner G, Koal T, Resch K, Kaever V. Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rates. Dig Dis Sci 2004;49:30–7.PubMedCrossRef

165.

Moghadasian MH. Dietary phytosterols reduce cyclosporine-induced hypercholesterolemia in apolipoprotein E-knockout mice. Transplantation 2006;81:207–13.PubMedCrossRef

166.

Lee MS. Cytokine synergism in apoptosis: its role in diabetes and cancer. J Biochem Mol Biol 2002;35:54–60.PubMed

167.

Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes 1989;38:641–7.PubMedCrossRef

168.

Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992;340:548.PubMedCrossRef

169.

Tohda G, Oida K, Higashi S, Hayashi T, Miyamori I. Interferon-alpha and development of type 1 diabetes: a case without insulin resistance. Diabetes Care 1998;10:1774.CrossRef

170.

Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549–58.PubMedCrossRef

171.

Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998;28:514–7.PubMedCrossRef

172.

Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002;16:225–43.PubMedCrossRef

173.

Psarakis HM. Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectr 2006;19:157–62.CrossRef

174.

Ferner RE. Drug-induced diabetes. Baillieres Clin Endocrinol Metab 1992;6:849–66.PubMedCrossRef

175.

Schein PS, O, Connell MJ, Blom J, Hubbard S, Magrath IT, Bergevin P, et al. Clinical antitumor activity and toxicity of streptozocin (NSC-85998). Cancer 1974;34:993–1000.PubMedCrossRef

176.

Pavel ME, Baum U, Hahn EG, Hensen J. Doxorubicin and streptozocin after failed biotherapy for neuroendocrine tumors. Int J Gastrointest Cancer 2005;35:179–85.PubMedCrossRef

177.

Pandit MK, Burke J, Gustafson AB, Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993;118:529–39.PubMed

178.

Sestier C, Odent-Pogu S, Bonneville M, Maurel C, Lang F, Sai P. Cyclosporin enhances diabetes induced by low-dose streptozotocin treatment in mice. Immunol Lett 1985;10:57–60.PubMedCrossRef

179.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271–81.PubMedCrossRef

180.

Duran I, Le L, Saltman D, Singh W, Kocha R, Cheiken G, et al. A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs, Abstract no: 146). 2005, Jan. 27–9. Gastrointestinal Cancers Symposium, Hollywood, FL, USA.

181.

Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006;95:1148–54.PubMedCrossRef

182.

Ferrari S, Pieretti F, Verri E, Tolentinis L, Cedari M, Versari M, et al. Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cistplatin and high-dose methotrexate. Anticancer Drugs 2005;16:733–8.PubMedCrossRef

183.

Skinner R, Coterrill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. Br J Cancer 2000;82:1636–45.PubMedCrossRef

184.

Feuerstein M, editor. Handbook of cancer survivorship. New York, Springer; 2007.

Titel: Endocrine sequelae of cancer and cancer treatments
verfasst von: Charles J. Stava
Camilo Jimenez
Rena Vassilopoulou-Sellin
Publikationsdatum: 01.12.2007
Verlag: Springer US
Erschienen in: Journal of Cancer Survivorship / Ausgabe 4/2007
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-007-0038-6

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Endocrine sequelae of cancer and cancer treatments

Abstract

Introduction

Methods

Results

Discussion/conclusions

Implications for cancer survivors

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Introduction

Methods

Results

Discussion/conclusions

Implications for cancer survivors

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2007

Survivors on Cancer: The portrayal of survivors in print news

The willingness of general practitioners to be involved in the follow-up of adult survivors of childhood cancer

Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients

Late outcomes of colorectal cancer treatment: a FECS-EUROCARE study

Low-dose anthracyclines in childhood Acute Lymphoblastic Leukemia (ALL): no cardiac deterioration more than 20 years post-treatment

Acupuncture and fatigue: Current basis for shared communication between breast cancer survivors and providers

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie